HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 601–700 of 1,008
Zubrienė, A., Matulienė, J., Baranauskienė, L., Jachno, J., Torresan, J., Michailovienė, V., Cimmperman, P., & Matulis, D. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10062662 · Cited by 63
Zong, H., Gozman, A., Caldas-Lopes, E., Taldone, T., Sturgill, E. M., Brennan, S. K., Ochiana, S. O., Gomes-DaGama, E. M., Sen, S., Rodina, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.073 · Cited by 63
“…the stabilization of oncogenic clients such as BCR-ABL, NPM-ALK, and HER2 (Whitesell and Lindquist, 2005), and clinical translation of Hsp90 inhibitors to date has primarily focused on tumors driven by these and other known Hsp90 oncoclients (Moulick et al., 2011; Whitesell and Lindquist, 2005).”
BackgroundInfluentialBickel, D., & Gohlke, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115080 · Cited by 67
“While basal levels of HSP90 are needed for maintaining protein homeostasis under physiological conditions, the HSP90 machinery can be exploited by cancer cells to cope with proteotoxic stressors, such as a high mutation burden, hypoxia, and acidosis that are frequently found in the tumor microenvironment.(32,33) Accor…”
BackgroundLamoth, F., Juvvadi, P. R., Gehrke, C., Asfaw, Y. G., & Steinbach, W. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit530 · Cited by 62
“Hsp90 is an essential molecular chaperone in eukaryotes, controlling a large network of client proteins [6, 7].”
BackgroundKirschning, A., & Hahn, F. H. (2012) · Angewandte Chemie · doi:10.1002/ange.201107386 · Cited by 62
Lee, E. J., Yun, U.-J., Koo, K. H., Sung, J. Y., Shim, J., Ye, S.-K., Hong, K., & Kim, Y.-N. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.10.006 · Cited by 69
Sodero, A. O., Trovò, L., Iannilli, F., Van Veldhoven, P., Dotti, C. G., & Martin, M. G. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07079.x · Cited by 57
The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer
Hance, M. W., Nolan, K. D., & Isaacs, J. S. (2014) · Cancers · doi:10.3390/cancers6021065 · Cited by 66
“Hsp90 associates with a defined cohort of co-chaperones in an ATP-dependent manner to allow for precise regulation of its respective “client” proteins [3].”
BackgroundFriedland, J. C., Smith, D. L., Sang, J., Acquaviva, J., He, S., Zhang, C., & Proia, D. A. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9971-6 · Cited by 62
“During tumorigenesis, the chaperoning activity of Hsp90 may become co-opted by cancer cells, in turn conferring aberrant proliferative, survival, angiogenic and/or metastatic potential [15, 16].”
BackgroundInhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma
Okamoto, J., Mikami, I., Tominaga, Y., Kuchenbecker, K. M., Lin, Y., Bravo, D. T., Clément, G., Yagui‐Beltrán, A., Ray, M., Koizumi, K., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181839693 · Cited by 66
Pelz, J. O. W., Vetterlein, M. W., Grimmig, T., Kerscher, A., Moll, E.-M., Lazariotou, M., Matthes, N., Faber, M., Germer, C., Waaga-Gasser, A. M., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2784-6 · Cited by 62
Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications
Custodio, A., Méndez, M., & Provencio, M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.001 · Cited by 65
Böll, B., Eltaib, F. I., Reiners, K. S., von Tresckow, B., Tawadros, S., Simhadri, V. R., Burrows, F. J., Lundgren, K., Hansen, H. P., Engert, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0213 · Cited by 67
Molecular chaperones in mammary cancer growth and breast tumor therapy
Calderwood, S. K., & Gong, J. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23461 · Cited by 66
Wang, M., Shen, A., Zhang, C., Song, Z., Ai, J., Liu, H., Sun, L., Ding, J., Geng, M., & Zhang, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01106 · Cited by 62
Cellular senescence and protein degradation: Breaking down cancer
Deschênes-Simard, X., Lessard, F., Gaumont-Leclerc, M.-F., Bardeesy, N., & Ferbeyre, G. (2014) · Cell Cycle · doi:10.4161/cc.29335 · Cited by 61
Combination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria
Sulthana, S., Banerjee, T., Kallu, J., Vuppala, S. R., Heckert, B., Naz, S., Shelby, T., Yambem, O., & Santra, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01076 · Cited by 67
Jhaveri, K. L., Wang, R., Teplinsky, E., Chandarlapaty, S., Solit, D. B., Cadoo, K. A., Speyer, J. L., D’Andrea, G. M., Adams, S., Patil, S. N., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0879-5 · Cited by 62
Impact of Carcinogenic Chromium on the Cellular Response to Proteotoxic Stress
Ferreira, L. M. R., Cunha‐Oliveira, T., Sobral, M. C. M., Abreu, P. L., Alpoim, M. C., & Urbano, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194901 · Cited by 66
“For instance, HSP90 overexpression, which was observed in a broad spectrum of cancers, correlated with tumor growth, metastatic potential and resistance to chemotherapy [86,91,92].”
BackgroundHeat shock proteins as biomarkers of lung cancer
Mittal, S., & Rajala, M. S. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1736482 · Cited by 62
“Therefore, Hsp90 is considered as an important facilitator for “oncogene addiction” and for the maintenance of malignant phenotype.(60) Inducible Hsp90α in plasma was reported to be high in lung tumor patients as compared to normal healthy controls and the expression level was correlated with the development and progr…”
BackgroundRole of WTAP in Cancer: From Mechanisms to the Therapeutic Potential
Fan, Y., Li, X., Sun, H., Gao, Z., Zhu, Z., & Yuan, K. (2022) · Biomolecules · doi:10.3390/biom12091224 · Cited by 62
“indicated that Hsp90 stabilizes many tumor-promoting proteins [93].”
BackgroundTargeting HSF1 sensitizes cancer cells to HSP90 inhibition
Chen, Y., Chen, J., Loo, A. T., Jaeger, S. A., Bagdasarian, L., Yu, J., Chung, F. S., Korn, J. M., Ruddy, D. A., Guo, R., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.991 · Cited by 66
“HSP90 chaperone machinery enables mutated oncoproteins to escape from misfolding and degradation and allows for malignant transformation [2, 10, 11].”
BackgroundLamoureux, F., Thomas, C., Yin, M., Kuruma, H., Fazli, L., Gleave, M., & Zoubeidi, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3077 · Cited by 64
“Indeed, HSP90 interacts with several client proteins regulating proliferation and cell survival of tumor cells including growth factor receptors, cell-cycle regulators, and signaling kinases such as Akt or Raf-1 (7–9).”
Rao, A., Taylor, J. L., Chi-Sabins, N., Kawabe, M., Gooding, W. E., & Storkus, W. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0538 · Cited by 62
“peutic protocols predicated on the immune targeting of one or more alternateHSP90 client proteins that are commonly (over) expressed by tumor cells or tumor-associated stromal cells, such as beclin 1, cyclin B, EGFR, HER2/neu, IGF1-R, PDGFR, PIM-1, STAT3, survivin, TGFbR, VEGFR1, VEGFR2, among many others (16, 30).”
BackgroundSaxena, V., Naguib, Y. W., & Hussain, M. D. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.02.001 · Cited by 61
Expression of Hsp90 chaperome proteins in human tumor tissue
McDowell, C. L., Sutton, R. B., & Obermann, W. M. J. (2009) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2009.06.012 · Cited by 69
Hsp90 regulates the Fanconi anemia DNA damage response pathway
Oda, T., Hayano, T., Miyaso, H., Takahashi, N., & Yamashita, T. (2007) · Blood · doi:10.1182/blood-2006-08-038638 · Cited by 62
“binds to an ATP-bound form of Hsp90, stabilizing the interaction between Hsp90 and its client proteins.(2) In addition, Hsp70 coimmunoprecipitated with endogenous FANCA in these cells (data not shown).”
BackgroundInfluentialSekimoto, T., Oda, T., Pozo, F. M., Murakumo, Y., Masutani, C., Hanaoka, F., & Yamashita, T. (2010) · Molecular Cell · doi:10.1016/j.molcel.2009.12.015 · Cited by 68
“Given that Hsp90 activity is elevated in tumor cells (Kamal et al., 2003; Whitesell and Lindquist, 2005), the link between Hsp90 and Pol h provides important insights into aberrant genotoxic responses in tumor cells.”
The developmental genetics of biological robustness
Mestek, L., & Barkoulas, M. (2015) · Annals of Botany · doi:10.1093/aob/mcv128 · Cited by 64
“The classical example is heat shock protein 90 (HSP-90), which is an ATPdependent chaperone helping the maturation of a wide range of proteins through its association with various co-chaperones and cofactors (Whitesell and Lindquist, 2005).”
Ye, C., Tao, R. N., Cao, Q., Zhu, D., Wang, Y., Wang, J., Lü, J., Chen, E., & Li, L. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3535 · Cited by 67
Targeting p97 to Disrupt Protein Homeostasis in Cancer
Vekaria, P., Home, T., Weir, S. J., Schoenen, F. J., & Rao, R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00181 · Cited by 63
Demirsoy, Ş., Martin, S., Motamedi, S., van Veen, S., Holemans, T., den Haute, C. V., Jordanova, A., Baekelandt, V., Vangheluwe, P., & Agostinis, P. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx070 · Cited by 61
Uno, T., Kawai, Y., Yamashita, S., Oshiumi, H., Yoshimura, C., Mizutani, T., Suzuki, T., Chong, K. T., Shigeno, K., Ohkubo, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01085 · Cited by 61
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion
Zhang, S., Wang, C., Ma, B., Xu, M., Xu, S., Liu, J., Tian, Y., Fu, Y., & Luo, Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107879 · Cited by 60
Targeting Mitosis for Anti-Cancer Therapy
Sudakin, V., & Yen, T. J. (2007) · BioDrugs · doi:10.2165/00063030-200721040-00003 · Cited by 61
“[45] Phase I clinical trials are currently ongoing at three ceived as potentially effective anti-cancer compounds.[41] Recent centers in the US, and phase II studies are expected in the second studies revealed that Hsp90 is actively involved in kinetochore half of 2006.”
BackgroundMolecular Pathogenesis of Pancreatic Cancer and Clinical Perspectives
Matthaios, D., Zarogoulidis, P., Balgkouranidou, I., Chatzaki, Ε., & Kakolyris, S. (2011) · Oncology · doi:10.1159/000334449 · Cited by 66
Molecular Characterization of Macbecin as an Hsp90 Inhibitor
Martin, C. J., Gaisser, S., Challis, I. R., Carletti, I., Wilkinson, B., Gregory, M. A., Prodromou, C., Roe, S. M., Pearl, L. H., Boyd, S. M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701558c · Cited by 61
Lee, K., Lee, J., Han, S., Im, S., Kim, T., Oh, D., & Bang, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01944.x · Cited by 65
Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus
Lamoth, F., Juvvadi, P. R., & Steinbach, W. J. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.947239 · Cited by 57
Li, Q. Q., Hao, J.-J., Zhang, Z., Krane, L. S., Hammerich, K. H., Sanford, T. H., Trepel, J. B., Neckers, L., & Agarwal, P. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-00143-6 · Cited by 65
Park, H.-K., Jeong, H., Ko, E., Lee, G., Lee, J.-E., Lee, S. K., Lee, A.-J., Im, J. Y., Hu, S., Kim, S. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00978 · Cited by 57
A systematic atlas of chaperome deregulation topologies across the human cancer landscape
Esfahani, A. H., Sverchkova, A., Sáez-Rodríguez, J., Schuppert, A., & Brehme, M. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005890 · Cited by 61
“Attenuating the PN on the other hand, such as inhibiting chaperones like HSP70 and HSP90 or the UPS clearance machinery, are widely acknowledged as promising therapeutic avenues in cancers (Whitesell and Lindquist 2005, Miyata et al. 2013, Balchin et al. 2016, Li et al. 2016).”
BackgroundInfluentialDoi, T., Kurokawa, Y., Sawaki, A., Komatsu, Y., Ozaka, M., Takahashi, T., Naito, Y., Ohkubo, S., & Nishida, T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.009 · Cited by 61
Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors
Shevtsov, M. A., Multhoff, G., Mikhaylova, E. R., Shibata, A., Guzhova, I. V., & Margulis, B. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215284 · Cited by 60
Richter, K., & Büchner, J. (2006) · Cell · doi:10.1016/j.cell.2006.10.004 · Cited by 70
Stahl, M., Retzlaff, M., Nassal, M., & Beck, J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm628 · Cited by 65
“Hsp90, not required for the biogenesis of most proteins (21), acts as a more specialized chaperone in activating various near-native client proteins (22,23), including many important regulatory molecules such as steroid hormone receptors and kinases (24,25).”
BackgroundTargeting HSF1 for cancer treatment: mechanisms and inhibitor development
Chin, Y., Gumilar, K. E., Li, X., Tjokroprawiro, B. A., Lu, C., Lu, J., Zhou, M., Sobol, R. W., & Tan, M. (2023) · Theranostics · doi:10.7150/thno.82431 · Cited by 62
“Furthermore, many proteins associated with tumor cell survival are HSP90 client proteins, and tumor cells demonstrate greater dependence on HSP90 [100].”
The Hsp90 molecular chaperone governs client proteins by targeting intrinsically disordered regions
Kolhe, J. A., Babu, N. L., & Freeman, B. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.05.021 · Cited by 61
C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis
Brown, M. A., Foreman, K. W., Harriss, J. V., Das, C., Zhu, L., Edwards, M. A., Shaaban, S. A., & Tucker, H. O. (2015) · Oncotarget · doi:10.18632/oncotarget.2970 · Cited by 64
“HSP90 is a key chaperone involved in the proper folding of many cellular proteins and its deregulation is strongly implicated in a broad array of malignancies [13, 14].”
BackgroundBarrott, J. J., Hughes, P. F., Osada, T., Yang, X., Hartman, Z. C., Loiselle, D. R., Spector, N. L., Neckers, L., Rajaram, N., Hu, F., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.08.004 · Cited by 66
“The role of Hsp90 in mediating malignant behavior may be the result of oncogene driven factors that alter its normal cellular behavior(Whitesell and Lindquist, 2005).”
Contributions of Co-Chaperones and Post-Translational Modifications Towards Hsp90 Drug Sensitivity
Walton‐Diaz, A., Khan, S., Bourboulia, D., Trepel, J. B., Neckers, L., & Mollapour, M. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.88 · Cited by 63
Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors
Kusuma, B. R., Khandelwal, A., Gu, W., Brown, D. R., Liu, W., Vielhauer, G. A., Holzbeierlein, J. M., & Blagg, B. S. J. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.12.056 · Cited by 64
Gillis, J. L., Selth, L. A., Centenera, M. M., Townley, S. L., Sun, S., Plymate, S. R., Tilley, W. D., & Butler, L. M. (2013) · Oncotarget · doi:10.18632/oncotarget.975 · Cited by 61
“These “clients” include AR and a range of oncoproteins involved in diverse cellular pathways, making it an attractive target for prostate cancer [23, 24].”
BackgroundThakur, M. K., Heilbrun, L. K., Sheng, S., Stein, M. N., Liu, G., Antonarakis, E. S., Vaishampayan, U. N., Dzinic, S. H., Li, X., Freeman, S., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0307-6 · Cited by 64
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC
Ojha, R., Huang, H.-L., HuangFu, W., Wu, Y.-W., Nepali, K., Lai, M.-J., Su, C.-J., Sung, T.-Y., Chen, Y.-L., Pan, S., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.006 · Cited by 59
Molecular Mechanisms of Heat Shock Factors in Cancer
Puustinen, M. C., & Sistonen, L. (2020) · Cells · doi:10.3390/cells9051202 · Cited by 63
Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model disease
Amaral, M. D. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0251-x · Cited by 63
“of malignant cells through facilitation of their rapid somatic evolution (Whitesell and Lindquist 2005).”
BackgroundMethodKubo, M., Kanaya, N., Petrossian, K., Ye, J., Warden, C., Liu, Z., Nishimura, R., Osako, T., Okido, M., Shimada, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2332-x · Cited by 59
“LBH589 induces tumor cell apoptosis that HSP90 and its co-chaperones modulate through downregulation of AKT, TNF-a, and NF-jB function [38].”
HSPB1 Enhances SIRT2-Mediated G6PD Activation and Promotes Glioma Cell Proliferation
Ye, H., Huang, H., Cao, F., Chen, M., Zheng, X., & Zhan, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164285 · Cited by 58
Wu, M., Bai, X., Xu, G., Wei, J., Zhu, T., Zhang, Y., Li, Q., Liu, P., Song, A., Zhao, L., et al. (2007) · PROTEOMICS · doi:10.1002/pmic.200600643 · Cited by 58
Nieto-Miguel, T., Gajate, C., González‐Camacho, F., & Mollinedo, F. (2007) · Oncogene · doi:10.1038/sj.onc.1210816 · Cited by 64
“Heat shock protein 90 (Hsp90) is a molecular chaperone that keeps the correct folding and function of various client proteins that promote cancer cell growth, including HER-2/Erb2, Akt, Raf-1, Bcr-Abl and mutated p53, and is overexpressed in many tumor cells (Whitesell and Lindquist, 2005).”
BackgroundTargeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy
Ren, X., Li, T., Zhang, W., & Yang, X. (2022) · Cells · doi:10.3390/cells11162556 · Cited by 61
“melanogaster and Arabidopsis thaliana model systems has demonstrated that HSP90 can function as a biochemical buffer conferring cancer cells an ability to tolerate mutated proteins and altered signal pathways [1].”
BackgroundInfluentialHeat stress: A risk factor for skin carcinogenesis
Calapre, L., Gray, E. S., & Ziman, M. R. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.039 · Cited by 61
“This results in accumulation of dysfunctional protein within the pre-cancerous and in tumour cells, being a hallmark of cancer (Whitesell and Lindquist, 2005; Whitesell et al., 1998).”
BackgroundHSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization
Azoitei, N., Diepold, K., Brunner, C., ROUHI, A. M., Genze, F., Becher, A., Kestler, H. A., Lint, J. V., Chiosis, G., Koren, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1017 · Cited by 60
“HSP90 is a highly conserved and ubiquitously expressed molecular chaperone involved in the correct folding and final maturation of a plethora of proteins, so-called HSP90 clients, in an effort to maintain cellular homeostasis (7, 8).”
Khandelwal, A., Hall, J. A., & Blagg, B. S. J. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo401027r · Cited by 57
Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones
Kang, B. H., & Altieri, D. C. (2009) · Oncogene · doi:10.1038/onc.2009.227 · Cited by 57
A new approach to understanding the molecular mechanisms through which estrogens affect cognition
Frick, K. M., Fernandez, S. M., & Harburger, L. L. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.11.004 · Cited by 55
“bind to estrogens and translocate to the nucleus [140].”
The Platelet-derived Growth Factor Receptor α Is Destabilized by Geldanamycins in Cancer Cells
Matei, D. E., Satpathy, M., Cao, L., Lai, Y.-C., Nakshatri, H., & Donner, D. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607012200 · Cited by 59
Shimp, S. K., Parson, C. D., Regna, N. L., Thomas, A. N., Chafin, C. B., Reilly, C. M., & Rylander, M. N. (2012) · Inflammation Research · doi:10.1007/s00011-012-0442-x · Cited by 63
Hughes, D., Guttenplan, J. B., Marcus, C. B., Subbaramaiah, K., & Dannenberg, A. J. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0149 · Cited by 57
RetractedUpregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
To, K. K. W., Robey, R. W., Zhan, Z., Bangiolo, L., & Bates, S. E. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0270 · Cited by 59
“Hsp90 is an ATP-dependent molecular chaperone that controls the intracellular trafficking and folding of diverse cellular proteins, particularly those involved in signal transduction, cell cycle regulation, and survival (17, 18).”
BackgroundNew, Highly Active Nonbenzoquinone Geldanamycin Derivatives by Using Mutasynthesis
Eichner, S., Floss, H. G., Sasse, F., & Kirschning, A. (2009) · ChemBioChem · doi:10.1002/cbic.200900246 · Cited by 56
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy
Thomas, S., & Münster, P. N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.026 · Cited by 62
“Inhibition of Hsp90 chaperone activity results in ubiquitin-mediated degradation of ERa by the proteasome [54].”
BackgroundHeat shock protein 90 inhibition: rationale and clinical potential
Den, R. B., & Lu, B. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012445574 · Cited by 63
“While ubiquitously expressed in unstressed normal cells, the HSP90 complex assists in the folding and function of a variety of client proteins [Whitesell and Lindquist, 2005].”
BackgroundHeat Shock Proteins In Cancer: Targeting the ‘Chaperones’
Nahleh, Z. A., Tfayli, A., Najm, A. A. A. M., Sayed, A. E., & Nahle, Z. A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.50 · Cited by 62
Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?
Luo, W., Rodina, A., & Chiosis, G. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s7 · Cited by 68
“Common to these hallmark traits is Hsp90, a protein that has the capacity to regulate key elements of each of these processes, suggesting that the chaperone is an indispensable controller of multiple proteins regulating these cancer hallmarks [1-6,18].”
BackgroundInfluentialCrowe, L. B., Hughes, P. F., Alcorta, D. A., Osada, T., Smith, A. P., Totzke, J., Loiselle, D. R., Lutz, I. D., Gargesha, M., Roy, D., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00006 · Cited by 57
Noormohammadi, A., Calculli, G., Gutiérrez-García, R., Khodakarami, A., Koyuncu, S., & Vílchez, D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2602-1 · Cited by 62
Protein stability and degradation in health and disease
(2019) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2018.09.002 · Cited by 47
Turnham, R. E., Smith, F. D., Kenerson, H. L., Omar, M. H., Golkowski, M., Garcia, I., Bauer, R., Lau, H.-T., Sullivan, K. M., Langeberg, L. K., et al. (2019) · eLife · doi:10.7554/elife.44187 · Cited by 61
Extracellular Hsp90α Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer
Hou, Q., Chen, S., An, Q., Li, X., Fu, Y., & Luo, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147747 · Cited by 58
“In cancer cells, the necessary guardian function of Hsp90α as an intracellular molecular chaperone is subverted to stabilize activated oncoproteins and buffer cellular stress to allow malignant transformation [51].”
BackgroundBarluenga, S., Wang, C., Fontaine, J., Aouadi, K., Beebe, K. E., Tsutsumi, S., Neckers, L., & Winssinger, N. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800233 · Cited by 61
Vaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55
“Thus, the Hsp90 inhibitor 17AAG affects multiple oncogenic signaling pathways, many of which participate in antagonizing p53 signaling.(18) Therefore, it is very likely that other events besides downregulation of MDMX could contribute to the apoptotic synergism between 17AAG and Nutlin.”
BackgroundPotential benefits of phytochemicals from Azadirachta indica against neurological disorders
Sandhir, R., Khurana, M., & Singhal, N. K. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105023 · Cited by 57
Hsp90: From Cellular to Organismal Proteostasis
Somogyvári, M., Khatatneh, S., & Sőti, C. (2022) · Cells · doi:10.3390/cells11162479 · Cited by 58
“Under normal conditions, it is one of the most abundant members of HSPs and represents 1–2% of all cellular proteins [5].”
BackgroundKunachowicz, D., Król-Kulikowska, M., Raczycka, W., Sleziak, J., Błażejewska, M., & Kulbacka, J. (2024) · Cancers · doi:10.3390/cancers16081500 · Cited by 54
“…of a biochemical buffer for many genetic mutations present in tumor cells, allowing for the achievement or maintenance of the functions of mutated proteins while permitting cancer cells to tolerate the impaired signaling mediated by these oncogenic factors, and thereby to escape apoptosis [174].”
BackgroundMagnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery
Chen, Y., Sun, H., Li, Y., Han, X., Yang, Y., Chen, Z., Zhao, X., Qian, Y., Liu, X., Zhou, F., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.07.033 · Cited by 100
“Hsp90, a highly conserved molecular chaperone overexpressed in tumors, stabilizes client proteins and shields them from therapeutic stress, presenting a major thermotherapy challenge [157].”
Hombach, A., Ommen, G., Chrobak, M., & Clos, J. (2012) · Cellular Microbiology · doi:10.1111/cmi.12057 · Cited by 57
“This chemical knockout approach also led to the establishment of Hsp90 inhibitors as prospective cancer therapeutics (Whitesell and Lindquist, 2005).”
BackgroundGaude, H., Aznar, N., Delay, A., Brès, A., Buchet-Poyau, K., Caillat, C., Vigouroux, A., Rogon, C., Woods, A., Vanacker, J.-M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.342 · Cited by 57
DeZwaan, D. C., & Freeman, B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.02.005 · Cited by 58
Usmani, S. Z., Bona, R., Chiosis, G., & Li, Z. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-40 · Cited by 55
“HSP90 family of proteins are ubiquitous molecular chaperones that are involved in folding, activation, maturation and assembly of many proteins (referred to as HSP90 client proteins or HSP90 clientele) that include essential mediators of signal transduction and cell cycle progression [10].”
BackgroundKarkoulis, P. K., Stravopodis, D. J., Margaritis, L. H., & Voutsinas, G. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-481 · Cited by 58
“The Hsp90 chaperone complex maintains the correct folding, cellular localization and activity of a broad range of protein clients that are implicated in various signal transduction pathways involved, among others, in cell proliferation, differentiation and survival [7,10].”
Mechanistic Studies on Hsp90 Inhibition by Ansamycin Derivatives
Onuoha, S. C., Mukund, S. R., Coulstock, E. T., Sengerová, B., Shaw, J. S., McLaughlin, S. H., & Jackson, S. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.065 · Cited by 58
MLK3 Signaling in Cancer Invasion
Rattanasinchai, C., & Gallo, K. A. (2016) · Cancers · doi:10.3390/cancers8050051 · Cited by 56
“Thus this chaperone complex is important for the stability and function of several key signaling molecules in cancer [60,62].”
BackgroundNagane, M., Yasui, H., Kuppusamy, P., Yamashita, T., & Inanami, O. (2021) · Journal of Radiation Research · doi:10.1093/jrr/rrab032 · Cited by 62
“Heat shock protein 90 (HSP90) is a well-conserved, highly expressed molecular chaperone protein that assists in protein folding and stabilization [87].”
BackgroundPerotti, C., Liu, R., Parusel, C. T., Böcher, N., Schultz, J., Bork, P., Pfitzner, E., Groner, B., & Shemanko, C. S. (2008) · Breast Cancer Research · doi:10.1186/bcr2193 · Cited by 53
“Chemotherapeutic drugs, such as 17-AAG, inhibit HSP90 and usually result in the degradation of HSP90 client proteins [80].”
BackgroundHeat shock protein 90: a unique chemotherapeutic target.
Cullinan, S., & Whitesell, L. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.001 · Cited by 64
Self-citationNiu, X., Zhu, Y., Ding, C., Ma, J., Wei, P., Lin, Y., Fang, W., He, Q., Li, C., Cheng, J., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202306778 · Cited by 54
Yao, C., Wei, J., Wang, Z., Ding, H., Li, D., Yan, S., Yang, Y., & Gu, Z. (2012) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-012-9423-5 · Cited by 54
“This preserves folding of nascent polypeptides, prevents protein aggregation, and ensures specialized intracellular trafficking of client proteins [26, 42–44].”
FLT3 inhibition as a targeted therapy for acute myeloid leukemia
Sanz, M. Á., Burnett, A. K., Lo‐Coco, F., & Löwenberg, B. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833118fd · Cited by 54
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.